PMID- 30815266
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231120
IS  - 2052-8426 (Print)
IS  - 2052-8426 (Electronic)
IS  - 2052-8426 (Linking)
VI  - 6
IP  - 1
DP  - 2018 Apr
TI  - HIV Universal Vaccine.
LID - 5 [pii]
AB  - BACKGROUND: For many deadly viruses, there are no preventive and / or therapeutic 
      vaccines approved by health authorities World-wide (e.g., HIV, Ebola, Dengue, and 
      many others). Although, for some viruses, prophylactic vaccines are very 
      effective (e.g., HBV, and many others).In this realm, we design, manufacture, 
      test, and streamline into the clinics novel viral universal vaccines (VUV). VUV 
      have such unique features, that medical vaccination or natural infection induced 
      immunity against some viruses (e.g., HBV) upon the VUV's administration to the 
      infected with other, different viruses patients, is redirected against these 
      other, newly infecting viruses (e.g., HIV). SPECIFIC AIM: The specific aim of 
      this work was biomolecular engineering of the HIV universal vaccine comprising 
      the two main functional domains: CD4 or anti-gp120 - as the HIV tagging domain 
      and HBsAg - as the immune response eliciting domain, so that upon its 
      administration the HBV medical immunization or natural infection induced immunity 
      would be redirected, accelerated, and amplified to fight the HIV infection. 
      HEALTHY DONORS AND PATIENTS: Per the Institutional Review Board approval and in 
      compliance with the Declaration of Helsinki, all healthy donors and patients were 
      presented with the Patients' Bill of Rights and provided Patient Informed 
      Consent. All the procedures were pursued by the licensed medical doctors. METHODS 
      & RESULTS: We have biomolecularly engineered HIV universal vaccine (HIVUV) 
      comprising human CD4 or anti-gp120 and HBsAg of HBV. By immunoblotting and 
      magnetic activated molecular sorting, we have demonstrated high specificity of 
      this vaccine in binding HIV. By flow cytometry and nuclear magnetic resonance, we 
      have demonstrated high efficacy of these vaccines to engage HBV immunized 
      patients' immune system against HIV. Administration of HIVUV to blood or lymph of 
      the HIV+ patients resulted in rapid reduction of the HIV viremia down to 
      undetectable. It also resulted in protection of populations of CD4+ cells against 
      HIV caused decline. CONCLUSIONS: We have demonstrated the proof of concept for 
      high efficacy of VUV, specifically HIVUV, in annihilating HIV. Nevertheless, the 
      same compositions, processes, and methods, for persons skilled in biotechnology, 
      pharmacogenomics, and molecular medicine, are adaptable for other deadly viral 
      infections, which we vigorously pursue.
FAU - Malecki, Marek
AU  - Malecki M
AD  - Phoenix Biomolecular Engineering Foundation (PBMEF), San Francisco, CA, USA.
FAU - Saetre, Bianka
AU  - Saetre B
AD  - Phoenix Biomolecular Engineering Foundation (PBMEF), San Francisco, CA, USA.
LA  - eng
GR  - P41 GM103399/GM/NIGMS NIH HHS/United States
PT  - Journal Article
DEP - 20180430
PL  - Denmark
TA  - Mol Cell Ther
JT  - Molecular and cellular therapies
JID - 101624707
PMC - PMC6388684
MID - NIHMS966594
OTO - NOTNLM
OT  - Acquired Immunodeficiency Syndrome
OT  - Cluster of Differentiation 4
OT  - HPV: Human Papilloma Virus
OT  - HPVV: Human Papilloma Virus Vaccine
OT  - Hepatitis B Virus
OT  - Hepatitis B Virus Vaccine
OT  - Human Immunodeficiency Virus
OT  - Human Immunodeficiency Virus Vaccine
OT  - Vaccine
OT  - Virus universal vaccine
OT  - glycoprotein 120
EDAT- 2019/03/01 06:00
MHDA- 2019/03/01 06:01
PMCR- 2019/02/25
CRDT- 2019/03/01 06:00
PHST- 2019/03/01 06:00 [entrez]
PHST- 2019/03/01 06:00 [pubmed]
PHST- 2019/03/01 06:01 [medline]
PHST- 2019/02/25 00:00 [pmc-release]
AID - 5 [pii]
AID - 10.26781/2052-8426-2018-05 [doi]
PST - ppublish
SO  - Mol Cell Ther. 2018 Apr;6(1):5. doi: 10.26781/2052-8426-2018-05. Epub 2018 Apr 
      30.